ArticleJournal of cellular and molecular medicine2025
Targeting CD19 CAR-T With MND Promoter Enhances Tumour Killing.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.Journal for immunotherapy of cancer · 2026Article
- Targeting CD19 CAR-T With MND Promoter Enhances Tumour Killing.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Although Chimeric antigen receptor (CAR) T cell therapy has demonstrated a high remission rate in B cell acute lymphoblastic leukaemia, concerns regarding toxicity and disease recurrence remain. Different promoters can modulate the expression levels of CAR molecules on the cell surface. In this study, we systematically compared four distinct promoters (MND, MSCV, EF-1α and CMV). Our findings revealed that while these promoters exhibited similar characteristics, the MND promoter demonstrated superior viral packaging and transduction efficiency. Furthermore, it enhanced the anti-leukaemia efficacy by increasing the proportion of naïve T cells involved in the cytotoxic process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.